135 related articles for article (PubMed ID: 19223878)
21. Glycemic targets for patients with type 2 diabetes mellitus.
Hamnvik OP; McMahon GT
Mt Sinai J Med; 2009 Jun; 76(3):227-33. PubMed ID: 19421966
[TBL] [Abstract][Full Text] [Related]
22. Diabetes update 2006: urgency for new approaches.
Gavin JR
Ethn Dis; 2007; 17(2 Suppl 2):S2-23-7. PubMed ID: 17684810
[No Abstract] [Full Text] [Related]
23. Type 2 diabetes market.
Gershell L
Nat Rev Drug Discov; 2005 May; 4(5):367-8. PubMed ID: 15902771
[No Abstract] [Full Text] [Related]
24. Evaluating the Cardiovascular Safety of New Medications for Type 2 Diabetes: Time to Reassess?
Smith RJ; Goldfine AB; Hiatt WR
Diabetes Care; 2016 May; 39(5):738-42. PubMed ID: 27208377
[TBL] [Abstract][Full Text] [Related]
25. Financial conflicts of interest are related to voting patterns at FDA Advisory Committee meetings.
Lurie P
MedGenMed; 2006 Oct; 8(4):22. PubMed ID: 17415305
[No Abstract] [Full Text] [Related]
26. Financial conflicts of interest and the Food and Drug Administration's Advisory Committees.
Steinbrook R
N Engl J Med; 2005 Jul; 353(2):116-8. PubMed ID: 16014880
[No Abstract] [Full Text] [Related]
27. Diabetic cardiovascular disease lost in translation between endocrinology and cardiology.
Dagdelen S
Am J Cardiol; 2008 Oct; 102(8):1115-6. PubMed ID: 18929722
[No Abstract] [Full Text] [Related]
28. Should recent experiences with CVOTs for oral hypoglycemic drugs allow us to rethink the regulatory paradigm?
Meyer RJ
Clin Pharmacol Ther; 2015 Nov; 98(5):467-9. PubMed ID: 26234476
[TBL] [Abstract][Full Text] [Related]
29. Economic implications with newer agents to reduce cardiovascular risk in diabetes.
McAdam-Marx C
Am J Manag Care; 2018 Aug; 24(13 Suppl):S279-S285. PubMed ID: 30160395
[TBL] [Abstract][Full Text] [Related]
30. Drugs and diabetes: understanding the new breed of cardiovascular safety trials.
Adler AI
Lancet Diabetes Endocrinol; 2013 Nov; 1(3):175-7. PubMed ID: 24622361
[No Abstract] [Full Text] [Related]
31. Novel diabetes drugs to face higher hurdles?
Opar A
Nat Rev Drug Discov; 2007 Sep; 6(9):687-9. PubMed ID: 17907340
[No Abstract] [Full Text] [Related]
32. Rethinking the appraisal and approval of drugs for type 2 diabetes.
Naci H; Lehman R; Wouters OJ; Goldacre B; Yudkin JS
BMJ; 2015 Oct; 351():h5260. PubMed ID: 26452524
[No Abstract] [Full Text] [Related]
33. Therapy and clinical trials: diabetes and cardiovascular risk.
Peter R
Curr Opin Lipidol; 2008 Feb; 19(1):101-3. PubMed ID: 18196995
[No Abstract] [Full Text] [Related]
34. Assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment vs. risk aversion.
Zannad F; Stough WG; Lipicky RJ; Tamargo J; Bakris GL; Borer JS; Alonso García Mde L; Hadjadj S; Koenig W; Kupfer S; McCullough PA; Mosenzon O; Pocock S; Scheen AJ; Sourij H; Van der Schueren B; Stahre C; White WB; Calvo G
Eur Heart J Cardiovasc Pharmacother; 2016 Jul; 2(3):200-5. PubMed ID: 27418973
[TBL] [Abstract][Full Text] [Related]
35. Treatment of type 2 diabetes: one extreme to another.
Zaidi S
Arch Intern Med; 2009 Jul; 169(13):1246-7; author reply 1247. PubMed ID: 19597079
[No Abstract] [Full Text] [Related]
36. [Costs of antihyperglycemic drugs and consumables and treatment satisfaction in patients with type 2 diabetes. Results of the health care research study LIVE-DE (long-acting insulin glargine compared with NPH insulin in Germany)].
Hauner H; Kohlmann T; Landgraf W; Holle R; Pirk O; Scholten T
Dtsch Med Wochenschr; 2009 Jun; 134(23):1207-13. PubMed ID: 19472091
[TBL] [Abstract][Full Text] [Related]
37. Report from the 2nd Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes and Cardiovascular Disease (D&CVD) EASD Study Group.
Schnell O; Standl E; Catrinoiu D; Genovese S; Lalic N; Skra J; Valensi P; Rahelic D; Ceriello A
Cardiovasc Diabetol; 2017 Mar; 16(1):35. PubMed ID: 28284218
[TBL] [Abstract][Full Text] [Related]
38. FDA needs more funding, NEJM says, amid questions about antidiabetes drug.
Tanne JH
BMJ; 2007 Aug; 335(7615):322. PubMed ID: 17703024
[No Abstract] [Full Text] [Related]
39. Settling for second best?
Pitts PJ
Nat Biotechnol; 2007 Jul; 25(7):715-6. PubMed ID: 17621285
[No Abstract] [Full Text] [Related]
40. [Economic evaluation of drugs. Effectiveness in diabetes therapy].
Schöffski O
Dtsch Med Wochenschr; 2008 Aug; 133 Suppl 4():S106-9; discussion S124-6. PubMed ID: 18686218
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
